ATE209690T1 - Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage - Google Patents

Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage

Info

Publication number
ATE209690T1
ATE209690T1 AT95912584T AT95912584T ATE209690T1 AT E209690 T1 ATE209690 T1 AT E209690T1 AT 95912584 T AT95912584 T AT 95912584T AT 95912584 T AT95912584 T AT 95912584T AT E209690 T1 ATE209690 T1 AT E209690T1
Authority
AT
Austria
Prior art keywords
mage
cancerical
determination
conditions
gene expression
Prior art date
Application number
AT95912584T
Other languages
English (en)
Inventor
Plaen Etienne De
Thierry Boon-Falleur
Bernard Lethe
Jean-Pierre Szikora
Smet Charles De
Patrick Chomez
Beatrice Gaugler
Den Eynde Benoit Van
Francis Brasseur
Jean-Jacques Patard
P Weynants
M Marchand
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/204,727 external-priority patent/US5512437A/en
Priority claimed from US08/209,172 external-priority patent/US5763165A/en
Priority claimed from US08/299,849 external-priority patent/US5612201A/en
Priority claimed from US08/346,774 external-priority patent/US5512444A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE209690T1 publication Critical patent/ATE209690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
AT95912584T 1994-03-01 1995-02-23 Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage ATE209690T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/204,727 US5512437A (en) 1994-03-01 1994-03-01 Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US08/209,172 US5763165A (en) 1994-03-10 1994-03-10 Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US08/299,849 US5612201A (en) 1991-05-23 1994-09-01 Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US08/346,774 US5512444A (en) 1994-03-01 1994-11-30 Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
PCT/US1995/002203 WO1995023874A1 (en) 1994-03-01 1995-02-23 Determination of cancerous conditions by mage gene expression

Publications (1)

Publication Number Publication Date
ATE209690T1 true ATE209690T1 (de) 2001-12-15

Family

ID=27498545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912584T ATE209690T1 (de) 1994-03-01 1995-02-23 Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage

Country Status (11)

Country Link
EP (1) EP0871765B1 (de)
JP (1) JPH09509832A (de)
KR (1) KR100316209B1 (de)
AT (1) ATE209690T1 (de)
AU (1) AU698310B2 (de)
CA (1) CA2184482A1 (de)
DE (1) DE69524264T2 (de)
FI (1) FI963393A7 (de)
NO (1) NO963589L (de)
NZ (1) NZ282536A (de)
WO (1) WO1995023874A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221593B1 (en) * 1996-10-03 2001-04-24 Ludwig Institute For Cancer Research Method for determining cancer by determining expression of MAGE-10
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
EP0972084A2 (de) 1997-04-11 2000-01-19 Micromet Gesellschaft für Biomedizinische Forschung mbH Primer und verfahren zur detektion von tumorzellmetastasen
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
JP2002523093A (ja) 1998-08-31 2002-07-30 アジェンシス，インコーポレイテッド Ｐｈｅｌｉｘ：癌において発現される精巣特異的タンパク質
US6733998B1 (en) * 1998-12-07 2004-05-11 Sloan-Kettering Institute For Cancer Research Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US6475794B1 (en) * 1999-10-08 2002-11-05 The Johns Hopkins University Converting diploidy to haploidy for genetic diagnosis
WO2002083945A2 (en) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
JP2024504912A (ja) 2020-12-30 2024-02-02 イミュノミック セラピューティックス， インコーポレイテッド 抗ｈｖｅｍ抗体
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
KR100316209B1 (ko) 2002-06-26
AU1968295A (en) 1995-09-18
FI963393A0 (fi) 1996-08-30
CA2184482A1 (en) 1995-09-08
EP0871765A4 (de) 1999-08-11
KR970701790A (ko) 1997-04-12
FI963393L (fi) 1996-08-30
WO1995023874A1 (en) 1995-09-08
FI963393A7 (fi) 1996-08-30
EP0871765B1 (de) 2001-11-28
NO963589L (no) 1996-10-31
DE69524264D1 (de) 2002-01-10
EP0871765A1 (de) 1998-10-21
NO963589D0 (no) 1996-08-28
DE69524264T2 (de) 2002-07-18
NZ282536A (en) 1998-07-28
AU698310B2 (en) 1998-10-29
JPH09509832A (ja) 1997-10-07

Similar Documents

Publication Publication Date Title
ATE209690T1 (de) Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
EP0288082A3 (de) Tumor-spezifische Bestimmung von CA125-Ovarial-Krebsantigen
DE3778948D1 (de) Teilchen, geeignet fuer die herstellung von tabletten als diagnostische reagenzien.
DE69110141D1 (de) Diagnostikvorrichtung und -verfahren für die Kolbenringabnutzung.
CA2137822A1 (en) Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
DE69433518D1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
NO960158D0 (no) Fremgangsmåte til diagnostisering av en lidelse ved å bestemme ekspresjon av GAGE-tumor-rejeksjonsantigenforlöpere
IT8022096A0 (it) Procedimento per la produzione di pasta secca, impianto per la sua attuazione, nonche' prodotto ottenuto.
DE68915758D1 (de) Blockkodierungsschema für die Übertragung von partiellen Bits.
IT8122489A0 (it) Procedimento per produrre un prodotto preliminare perl'ottenimento di silicio e, oppure carburo di silicio.
DE69523586D1 (de) Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen
DE69004300D1 (de) Verfahren zur Herstellung wellenförmiger Imbiss-Chips.
DE69004907D1 (de) Metallische Verstärkung für Leiste oder Dichtung, insbesondere für die Kraftfahrzeugindustrie.
AU4897096A (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
DE69502005D1 (de) Eine Suspension brauchbar für die Abscheidung lumineszierender Stoffe mittels Elektrophorese, insbesondere für die Herstellung flacher Bildschirme
IT8219323A0 (it) Metodo e apparecchiatura per laproduzione di gas di sintesi.
IT1226719B (it) Metodo per produrre fluororesina tenera polimerizzata ad innesto.
DE69132420D1 (de) Zusammensetzung zur immunologischen analyse und ihr herstellungsverfahren unter verwendung von antigen, sowie immunologische diagnosekits für die chagas-krankheit
IT8221204A0 (it) Apparecchio per la produzione di un filato ad effetto.
DE59809600D1 (de) Doppelmetallcyanid-katalysatoren für die herstellung von polyetherpolyolen
IT1184668B (it) Linfochina,suo anticorpo specifico monoclonale e relativo procedimento di produzione
NL185987C (nl) Werkwijze voor de vervaardiging van een bourdonbuis, bourdonbuis verkregen door toepassing van die werkwijze en manometer voorzien van een dergelijke bourdonbuis.
WO2002031500A3 (de) Auf dem nachweis von igf-irss und irs-1 beruhendes diagnose- bzw. klassifizierungsverfahren für carcinome
WO1997010258A3 (de) Antikörper gegen an oberflächen von carcinom-zellen ausserhalb von desmosomen exponierte epitope desmosomaler cadherine
IT8125022A0 (it) Procedimento per la fabbricazione di trefoli di acciaio ad alta resistenza.